Jupiter Wellness Announces First Patient Dosing for Double-Blinded Placebo Controlled Trial of JW-300 for the Treatment of First Degree Burns

JUPITER, FL / October 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced the enrollment and dosing of the first patient in the study. The double-blinded placebo-controlled study will enroll 50 patients with newly diagnosed first degree burns of superficial […]